Tag: Cancer immunotherapy
Glenmark Pharmaceuticals set to begin clinical trial of GRC 54276 in US
Glenmark Pharmaceuticals, through its subsidiary Glenmark Specialty, is set to begin a first-in-human, phase 1/2 clinical study of GRC 54276 in the US for the ... Read More
Gilead to acquire stake in cancer immunotherapy company Pionyr Immunotherapeutics
Gilead Sciences has agreed to acquire a stake of 49.9% in California-based cancer immunotherapy company Pionyr Immunotherapeutics, for $275 million. The pharma major has also ... Read More
Cancer immunotherapy company EpicentRx raises $35m in Series D round
EpicentRx, a cancer immunotherapy company based in California, has secured $35 million of capital through a Series D financing round to support the development of ... Read More
MicroMedicine to introduce new white blood cell isolation technology at SITC annual conference
MicroMedicine, a US life sciences technology company, will launch Sorterra Cell Isolation System, a white blood cell isolation technology, at the 34th Society for Immunotherapy ... Read More
Compugen kickstarts phase 1 trial of cancer immunotherapy COM701
Israeli pharma company Compugen has dosed the first patient in the phase 1 clinical trial which is evaluating the company’s cancer immunotherapy antibody COM701 in ... Read More